Prevention of Neuropathic Pain From Oxaliplatin by Photobiomodulation

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Peripheral neuropathy is one of the most common side effects of oxaliplatin (OXA)-based chemotherapy for patients treated for digestive cancers, disabling and dose-limiting. Several strategies have been studied for the treatment of oxaliplatin-related sensory neuropathy. Several pharmacological and non-pharmacological therapeutic strategies have been explored to relieve peripheral neuropathic pain. Non-pharmacological interventions have been shown to be potentially beneficial for patients suffering from chemotherapy-induced neurotoxicity. The objective of this prospective study is to evaluate the effectiveness of photobiomodulation on the reduction of neuropathic pain in patients who developed painful, cumulative peripheral neuropathy that appeared under the effect of the treatment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Recent diagnosis of digestive cancer

• 12 planned cycles of oxaliplatin

• Ability to understand and willingness to sign an informed consent form before starting any study procedures

• Patient benefiting from French health insurance

Locations
Other Locations
France
CHP Saint-Grégoire
RECRUITING
Saint-grégoire
Contact Information
Primary
Morgane Pihan, MD
mpihan@vivalto-sante.com
+33 2 93 23 97 80
Time Frame
Start Date: 2023-05-31
Estimated Completion Date: 2025-04
Participants
Target number of participants: 70
Treatments
No_intervention: Control
Patients will not receive any intervention during their oxaliplatin chemotherapy cycles.
Experimental: Experimental
Patients will receive three photobiomodulation sessions per week during their oxaliplatin chemotherapy cycles
Related Therapeutic Areas
Sponsors
Leads: Saint-Gregoire Private Hospital Center

This content was sourced from clinicaltrials.gov